Search results
Results from the WOW.Com Content Network
For children with MRSA-infected bone or joints, treatment is individualized and long-term. Neonates can develop neonatal pustulosis as a result of topical infection with MRSA. [4] Clindamycin is not approved for the treatment of MRSA infection, but it is still used in children for soft-tissue infections. [4]
Ceftaroline fosamil / s ɛ f ˈ t ær oʊ l iː n /, brand name Teflaro in the US and Zinforo in Europe, [1] [2] is a cephalosporin antibiotic with anti-MRSA activity. [3] Ceftaroline fosamil is a prodrug of ceftaroline. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria.
Effective for gram-positive, gram-negative, anaerobic, and against multi-antibiotic resistant bacteria (such as Staphylococcus aureus [MRSA] and Acinetobacter baumannii), but not effective for Pseudomonas spp. and Proteus spp. Teeth discoloration and same side effects as tetracycline. Not to be given to children and pregnant or lactating women.
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. [9] [10] Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
Resistance to these antibiotics has also led to the use of new, broad-spectrum anti-Gram-positive antibiotics, such as linezolid, because of its availability as an oral drug. First-line treatment for serious invasive infections due to MRSA is currently glycopeptide antibiotics (vancomycin and teicoplanin). A number of problems with these ...
Vancomycin is a glycopeptide antibiotic medication used to treat certain bacterial infections. [7] It is administered intravenously (injection into a vein) to treat complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. [8]
A Cochrane review found that while it is an effective treatment for shigellosis it also produces more significant adverse effects than other antibiotic drugs. [43] Staphylococcus aureus infections: No: No: No: In vitro and in vivo activity against both non-resistant and methicillin-resistant Staphylococcus aureus (MRSA) infections. [44] [45 ...
A review of investigational antibiotics shows that several new agents will become available in the coming years, even though the pace of antimicrobial research has proven far too slow. Overuse of antimicrobial agents and problems with infection control practices have led to the development of multidrug-resistant gram-negative bacterial infections.